CDK4 and neoplasm: The observed Ki67 inhibition achieved by single-agent PF-06873600 was less than that observed for CDK4/6i ribociclib (mean inhibition ∼60%–70% at 600 mg daily) although the latter was measured in multiple tumor types (12).